Amlodipine (versus unexposed)

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Weber-Schoendorfer, 2008 Mito, 2019 Ishikawa (Controls unexposed, sick), 2023 31.42[0.69; 2.93]119124not evaluable Major congenital malformations Weber-Schoendorfer, 2008 Mito, 2019 Ishikawa (Controls unexposed, sick), 2023 31.46[0.68; 3.15]99124not evaluable Limb defects Weber-Schoendorfer, 2008 13.26[0.16; 64.54]332not evaluable Growth parameters and prematurity Preterm (< 37 weeks) Weber-Schoendorfer, 2008 Mito, 2019 Vaclavik, 2024 32.01[0.67; 6.00]105169not evaluable Low birth weight (< 2500g) Mito, 2019 Vaclavik, 2024 21.41[0.23; 8.44]61135not evaluable Maternal consequences Caesarean Vaclavik, 2024 12.82[2.35; 3.38]-221not evaluable Gestational diabetes Mito, 2019 10.29[0.08; 1.02]2748not evaluable Preeclampsia Mito, 2019 10.91[0.45; 1.85]5848not evaluable Neonatal disorders Low Apgar score (< 7) (NOS) Vaclavik, 2024 11.95[1.55; 2.46]-88not evaluable Intrauterine deaths Early intrauterine death (< 22 weeks) Weber-Schoendorfer, 2008 11.96[0.73; 5.23]6436not evaluable Elective/induced termination of pregnancy Weber-Schoendorfer, 2008 11.44[0.33; 6.25]3238not evaluable Late intrauterine deaths (> 22 weeks) Weber-Schoendorfer, 2008 13.67[0.43; 31.29]736not evaluable0.0100.01.0

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons